Beigene Ltd (ADR) (NASDAQ:BGNE) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 19, 2016
Zacks Investment Research has upgraded Beigene Ltd (ADR)(NASDAQ:BGNE) to Hold in a report released on 9/19/2016.
Having a price of $32.54, Beigene Ltd (ADR) (NASDAQ:BGNE) traded 5.39% lower on the day. With the last stock price up 6.78% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. The company has been tracking to a 50-day moving average of $28.39 and two hundred day moving average of $28.93. Trading volume was was up over the average, with 142,109 shares of BGNE changing hands over the typical 49,775 shares.
See Graph Below:
With a market cap of $0.0, Beigene Ltd (ADR) has a P/E of 0 with a 52 week low of $22.51 and a 52 week high of $35.60.
General Information About Beigene Ltd (ADR) (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, and as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.